Search | IOVS | ARVO Journals

Showing 1 – 20 of 46

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Enhanced Hammerhead Ribozyme Function in vivo : Developing Therapeutic Space for Catalytic RNAs

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6093.

ARVO Annual Meeting Abstract June 2023

Investigating Properties of a Novel Human Rhodopsin Mutation Causing Retinitis Pigmentosa

Andrew Schwartz; Jason M Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4504.

ARVO Annual Meeting Abstract June 2023

Kinetically Enhanced Hammerhead Ribozymes Cleave Large Structured Target mRNAs

Jason M Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):800.

ARVO Annual Meeting Abstract June 2023

Systematic bioinformatics evaluation of mutation-dependent versus mutation-independent knockdown nucleic acid therapeutic strategies for dominant genetic diseases

Erika Wang Zheng; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1869.

ARVO Annual Meeting Abstract June 2023

Multivariable bioinformatics investigation to identify functional sites in 5’ untranslated regions of RHO mRNAs in animal models

Adetayo Oladele-Ajose; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1858.

ARVO Annual Meeting Abstract June 2022

RNA Structure-Function Properties of Enhanced Hammerhead Ribozymes with High Catalytic Efficiency

Jack M Sullivan; Jason Myers

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):78 – A0051.

ARVO Annual Meeting Abstract June 2022

Synthetic Nuclease Resistant Enhanced Hammerhead Ribozymes for Nucleic Acid Ocular Therapeutics

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):55 – A0028.

ARVO Annual Meeting Abstract June 2022

A novel homozygous nonsense mutation in the PDE6C gene discovered in a patient with achromatopsia

Mark Seraly; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):140 – A0320.

ARVO Annual Meeting Abstract June 2022

Cross-Ancestry Glaucoma Genetic Risk Score in Hispanic Veterans in the Million Veteran Program

Andrea R Waksmunski; Tyler Kinzy; Lauren A Cruz; Cari L Nealon; Christopher W Halladay; Scott A Anthony; Paul B Greenberg; Jack M Sullivan; Wen-Chih Wu; Sudha K Iyengar; Dana C Crawford; Neal Peachey; Jessica Cooke Bailey

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1129.

ARVO Annual Meeting Abstract June 2022

Association among basement membrane diseases of the eye: Fuchs endothelial corneal dystrophy (FECD), anterior basement membrane dystrophy (ABMD) and age-related macular degeneration (AMD)

Michael Shi; Henry Greyner-Almeida; Alexandra Sima; Teigen Ruster; Patricia Gianfagna; Brendan Plotke; Jack M Sullivan; Amy E Millen; Sangita P Patel

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3547 – A0127.

ARVO Annual Meeting Abstract June 2021

POAG genetic risk score performs worse in African-descent than European-descent samples, highlighting need for expanded genetic studies in diverse populations

Jessica Cooke Bailey; Tyler G. Kinzy; Cari Nealon; Christopher Halladay; Piana Simpson; Rachael Canania; Scott Anthony; David Roncone; Lea Sawicki-Rogers; Jenna Leber; Jacquelyn Dougherty; Paul B Greenberg; Wen-Chih Wu; Jack M Sullivan; Dana Crawford; Sudha K Iyengar

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1513.

ARVO Annual Meeting Abstract June 2021

Enhanced Hammerhead Ribozymes as Synthetic Nucleic Acid Ocular Therapeutics

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1203.

ARVO Annual Meeting Abstract June 2020

RNA Structure-Function Properties in Facilitated Hammerhead Ribozymes with Unprecedented Catalytic Rates

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2293.

ARVO Annual Meeting Abstract June 2020

Phenome-wide association analysis on risk variants for age-related macular degeneration reveals shared genetic influences with a wide range of disorders: the Million Veteran Program

Robert Igo; Tyler G Kinzy; Christopher W. Halladay; Dana C. Crawford; Paul B Greenberg; Jack M. Sullivan; Steven J. Fliesler; Wen-Chih Wu; Helene Choquet; Karina Patasova; Eric Jorgenson; Pirro G Hysi; Andrew J Lotery; Jessica Cooke Bailey; Neal S. Peachey; Sudha K Iyengar

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3518.

ARVO Annual Meeting Abstract June 2020

A Facilitated Hammerhead Ribozyme Rhodopsin Therapeutic with Catalytic Efficiency on Par with Ribonuclease A at Cellular Free Mg 2+ Levels

Jack M Sullivan; Jason Myers

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4481.

ARVO Annual Meeting Abstract June 2020

Computable phenotyping for primary open-angle glaucoma using electronic health records in the Million Veteran Program

Jessica Cooke Bailey; Cari L. Nealon; Christopher W. Halladay; Piana Krymskaya; Scott A. Anthony; David P. Roncone; Rachael Canania; Tyler G Kinzy; Robert Igo; Paul B Greenberg; Dana C. Crawford; Sudha K Iyengar; Jack M Sullivan; Wen-Chih Wu; Neal S. Peachey

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4555.

Articles December 2019

Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics

PDF

Edwin H. Yau; Robert T. Taggart; Mohammed Zuber; Alexandria J. Trujillo; Zahra S. Fayazi; Mark C. Butler; Lowell G. Sheflin; Jennifer B. Breen; Dian Yu; Jack M. Sullivan
TAGS: catalytic rna, opsin, rna, rna interference, rna, messenger, screening, therapeutics, cytokinesis, superior epigastric artery perforator flap, mutation
Trans. Vis. Sci. Tech.. 2019; 8(6):28. https://doi.org/10.1167/tvst.8.6.28

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Discovery of a Hammerhead Ribozyme with Enzyme Kinetics comparable to Protein Enzymes

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3406.

ARVO Annual Meeting Abstract July 2019

Facilitated Hammerhead Ribozymes- A New Therapeutic Modality for Inherited Retinal Degenerations

Jack M Sullivan; Jason Myers; Alexandria Trujillo; Mark Christian Butler; Zahra Fayazi; Jibin A. Punnoose; Kenneth A. Halvorsen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3412.

ARVO Annual Meeting Abstract July 2019

Rapid Preclinical Validation of PTGS Therapeutic Agents for Inherited Retinal Degenerations

Mark Christian Butler; Zahra Fayazi; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3414.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Enhanced Hammerhead Ribozyme Function in vivo : Developing Therapeutic Space for Catalytic RNAs

Investigating Properties of a Novel Human Rhodopsin Mutation Causing Retinitis Pigmentosa

Kinetically Enhanced Hammerhead Ribozymes Cleave Large Structured Target mRNAs

Systematic bioinformatics evaluation of mutation-dependent versus mutation-independent knockdown nucleic acid therapeutic strategies for dominant genetic diseases

Multivariable bioinformatics investigation to identify functional sites in 5’ untranslated regions of RHO mRNAs in animal models

RNA Structure-Function Properties of Enhanced Hammerhead Ribozymes with High Catalytic Efficiency

Synthetic Nuclease Resistant Enhanced Hammerhead Ribozymes for Nucleic Acid Ocular Therapeutics

A novel homozygous nonsense mutation in the PDE6C gene discovered in a patient with achromatopsia

Cross-Ancestry Glaucoma Genetic Risk Score in Hispanic Veterans in the Million Veteran Program

Association among basement membrane diseases of the eye: Fuchs endothelial corneal dystrophy (FECD), anterior basement membrane dystrophy (ABMD) and age-related macular degeneration (AMD)

POAG genetic risk score performs worse in African-descent than European-descent samples, highlighting need for expanded genetic studies in diverse populations

Enhanced Hammerhead Ribozymes as Synthetic Nucleic Acid Ocular Therapeutics

RNA Structure-Function Properties in Facilitated Hammerhead Ribozymes with Unprecedented Catalytic Rates

Phenome-wide association analysis on risk variants for age-related macular degeneration reveals shared genetic influences with a wide range of disorders: the Million Veteran Program

A Facilitated Hammerhead Ribozyme Rhodopsin Therapeutic with Catalytic Efficiency on Par with Ribonuclease A at Cellular Free Mg 2+ Levels

Computable phenotyping for primary open-angle glaucoma using electronic health records in the Million Veteran Program

Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics

Discovery of a Hammerhead Ribozyme with Enzyme Kinetics comparable to Protein Enzymes

Facilitated Hammerhead Ribozymes- A New Therapeutic Modality for Inherited Retinal Degenerations

Rapid Preclinical Validation of PTGS Therapeutic Agents for Inherited Retinal Degenerations

To View More...

You must be signed into an individual account to use this feature.